JP Morgan Downgrades Minerva Surgical to Underweight
JP Morgan analyst Robbie Marcus downgrades Minerva Surgical (NASDAQ:UTRS) from Overweight to Underweight.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Minerva Surgical Earnings Perspective: Return On Capital Employed
Minerva Surgical (NASDAQ:UTRS) brought in sales totaling $10.94 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 201.08%, resulting in a loss of $10.93 million.
SVB Leerink Maintains Outperform on Minerva Surgical, Lowers Price Target to $7
SVB Leerink analyst Danielle Antalffy maintains Minerva Surgical (NASDAQ:UTRS) with a Outperform and lowers the price target from $8 to $7.
Earnings Scheduled For May 11, 2022
Companies Reporting Before The Bell
• Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.
